Go Pro
→ Why major institutions are piling into this digital asset now (From Awesomely) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
$1.37
$1.42
$1.17
▼
$15.12
$6.13M1.13147,748 shs22,173 shs
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
$0.03
$0.03
$0.03
▼
$1.42
$1.60M2.964.85 million shsN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
$1.76
+19.7%		$1.43
$1.21
▼
$7.22
$7.33M2.2533,875 shs970,539 shs
Heatwurx Inc. stock logo
PCSA
Heatwurx
$2.06
-2.4%		$2.22
$1.67
▼
$14.24
$5.70M0.9977,958 shs9,591 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
0.00%-4.20%-4.20%-40.43%-92.13%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
0.00%0.00%0.00%0.00%-95.84%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
0.00%+15.79%+39.68%-24.46%-45.68%
Heatwurx Inc. stock logo
PCSA
Heatwurx
0.00%-0.96%+0.98%-19.53%-61.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
$1.37
$1.42
$1.17
▼
$15.12
$6.13M1.13147,748 shs22,173 shs
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
$0.03
$0.03
$0.03
▼
$1.42
$1.60M2.964.85 million shsN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
$1.76
+19.7%		$1.43
$1.21
▼
$7.22
$7.33M2.2533,875 shs970,539 shs
Heatwurx Inc. stock logo
PCSA
Heatwurx
$2.06
-2.4%		$2.22
$1.67
▼
$14.24
$5.70M0.9977,958 shs9,591 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
0.00%-4.20%-4.20%-40.43%-92.13%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
0.00%0.00%0.00%0.00%-95.84%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
0.00%+15.79%+39.68%-24.46%-45.68%
Heatwurx Inc. stock logo
PCSA
Heatwurx
0.00%-0.96%+0.98%-19.53%-61.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
1.00
SellN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
1.67
ReduceN/AN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
1.00
SellN/AN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
2.00
Hold$25.001,113.59% Upside

Current Analyst Ratings Breakdown

Latest ITRM, ENVB, NCNA, and PCSA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Heatwurx Inc. stock logo
PCSA
Heatwurx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/AN/AN/AN/A$1.81 per shareN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
$390K4.10N/AN/A($0.15) per share-0.20
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/AN/AN/AN/A$6.53 per shareN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/AN/AN/AN/A($0.11) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
-$8.77M-$12.65N/AN/AN/AN/A-168.04%-145.95%11/12/2026 (Estimated)
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$24.77M-$0.75N/AN/AN/AN/AN/A-65.54%N/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-$38.71M-$3.81N/AN/AN/AN/A-41.90%-33.69%11/12/2026 (Estimated)
Heatwurx Inc. stock logo
PCSA
Heatwurx
-$13.56M-$4.23N/AN/AN/AN/A-394.25%-244.46%10/29/2026 (Estimated)

Latest ITRM, ENVB, NCNA, and PCSA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/A-$0.76N/A-$0.76N/AN/A
8/14/2026Q2 2026
Heatwurx Inc. stock logo
PCSA
Heatwurx
-$1.00-$1.19-$0.19-$1.19N/AN/A
8/13/2026Q2 2026
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-$2.6514-$0.99+$1.6614N/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/AN/AN/AN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/AN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/AN/AN/AN/AN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/A
10.21
10.21
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/A
2.13
1.96
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/A
4.73
4.73
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/A
0.87
0.87

Institutional Ownership

CompanyInstitutional Ownership
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
13.82%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
9.21%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
44.00%
Heatwurx Inc. stock logo
PCSA
Heatwurx
91.93%

Insider Ownership

CompanyInsider Ownership
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
2.41%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
2.00%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
31.20%
Heatwurx Inc. stock logo
PCSA
Heatwurx
3.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
204.48 million4.37 millionNot Optionable
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
1053.29 million52.23 millionNot Optionable
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
304.16 million2.86 millionNot Optionable
Heatwurx Inc. stock logo
PCSA
Heatwurx
202.77 million2.67 millionNot Optionable

Recent News About These Companies

Processa Pharmaceuticals, Inc. (PCSA) M&A Call Prepared Remarks Transcript
July 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4927273-processa-pharmaceuticals-inc-pcsa-m-and-a-call-prepared-remarks-transcript
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC.
July 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/29/3335130/0/en/processa-pharmaceuticals-inc-announces-acquisition-of-vidya-therapeutics-inc-and-approximately-200-million-concurrent-private-placement-to-advance-btk-inhibitor-vt-7208-in-multiple.html
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/12/3217020/0/en/processa-pharmaceuticals-to-attend-44th-annual-j-p-morgan-healthcare-conference.html
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
January 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/05/3212860/0/en/processa-pharmaceuticals-completes-enrollment-of-20th-patient-for-formal-interim-analysis-in-phase-2-ngc-cap-breast-cancer-study.html
PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study
December 18, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2806083/pcsa-stock-soars-on-upbeat-clinical-update-from-breast-cancer-study?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2806083
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
December 17, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/12/17/3206931/0/en/processa-pharmaceuticals-provides-clinical-update-on-phase-2-study-in-metastatic-breast-cancer.html
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
November 5, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/11/05/3181589/0/en/processa-pharmaceuticals-announces-poster-presentation-of-adaptive-phase-2-3-pcs499-study-in-fsgs-at-asn-kidney-week-2025.html
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
August 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/07/3129263/0/en/processa-pharmaceuticals-secures-strategic-investment-and-evaluates-corporate-crypto-treasury-strategies.html
Processa Pharmaceuticals Provides Portfolio and Business Update
July 1, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/01/3108392/0/en/processa-pharmaceuticals-provides-portfolio-and-business-update.html
Processa Pares Gains on Equity Offer News
June 17, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/processa-pares-gains-on-equity-offer-news-3b7edf2c
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering
June 17, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/17/3100974/0/en/processa-pharmaceuticals-announces-pricing-of-7-million-public-offering.html
Processa Pharmaceuticals Enters Exclusive Licensing Agreement with Intact Therapeutics for PCS12852, Potential Treatment for Gastroparesis
June 17, 2025  |  quiverquant.comQ
Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate
June 17, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/17/3100689/0/en/processa-pharmaceuticals-signs-binding-term-sheet-granting-intact-therapeutics-exclusive-option-to-license-phase-2-gastroparesis-drug-candidate.html
Processa Pharmaceuticals to Showcase Next Generation Cancer Therapies at 2025 BIO International Convention
June 15, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/processa-pharmaceuticals-showcase-next-generation-cancer-therapies-2025-bio-international
Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025
June 13, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/13/3098971/0/en/processa-pharmaceuticals-to-engage-potential-partners-and-investors-at-bio-international-convention-2025.html
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
May 30, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/30/3091075/0/en/processa-pharmaceuticals-announces-presentation-and-publication-of-three-abstracts-at-2025-asco-annual-meeting.html
Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025
April 15, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/processa-pharmaceuticals-dr-david-young-to-present-at-world-orphan-drug-congress-usa-2025-1034584299
Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025
April 15, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/15/3061670/0/en/processa-pharmaceuticals-dr-david-young-to-present-at-world-orphan-drug-congress-usa-2025.html
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
March 18, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/18/3044510/0/en/processa-pharmaceuticals-to-present-at-the-medinvest-biotech-and-pharma-investor-conference.html
Processa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying Recently
February 21, 2025  |  insidermonkey.comhttps://www.insidermonkey.com/blog/processa-pharmaceuticals-inc-pcsa-among-the-cheapest-stocks-insiders-are-buying-recently-1459106/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Enveric Biosciences stock logo

Enveric Biosciences NASDAQ:ENVB

$1.37 0.00 (0.00%)
As of 08/28/2026 04:00 PM Eastern

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Iterum Therapeutics stock logo

Iterum Therapeutics NASDAQ:ITRM

$0.03 0.00 (0.00%)
As of 08/28/2026

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

NuCana stock logo

NuCana NASDAQ:NCNA

$1.76 +0.29 (+19.73%)
As of 08/28/2026 04:00 PM Eastern

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Heatwurx stock logo

Heatwurx NASDAQ:PCSA

$2.06 -0.05 (-2.37%)
As of 08/28/2026 04:00 PM Eastern

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas